trial

Risperidone Augmentation in Patients With Schizophrenia

NCTId NCT00289861
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 24 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2007-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-02
Primary completion
2007-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Massachusetts General HospitalLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

2
Oliver Freudenreich, M.D.Principal Investigator
Donald C. Goff, M.D.Principal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE4
Primary Completion Date
2007-03
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Oliver Freudenreich, M.D.
person
Donald C. Goff, M.D.
person